Trial Summary
What is the purpose of this trial?The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.
Eligibility Criteria
This trial is for adults over 18 with probable Dementia with Lewy bodies (DLB). Participants need an informant who checks on them weekly, must speak English well, consent to the study's protocol, and be able to attend up to six visits over five years. They should not have other neurological disorders like multiple sclerosis or brain tumors that could affect results.Treatment Details
The study aims to track changes in imaging biomarkers related to DLB using a technique called 18F-Flortaucipir PET scanning. It will explore how these changes correlate with cognitive and functional decline in participants over time.
1Treatment groups
Experimental Treatment
Group I: Dementia with Lewy BodiesExperimental Treatment1 Intervention
18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
Find a clinic near you
Research locations nearbySelect from list below to view details:
Mayo ClinicJacksonville, FL
Mayo ClinicRochester, MN
Loading ...
Who is running the clinical trial?
Kejal KantarciLead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)Collaborator